Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Dose-Finding Phase II Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo Following a Single Intramuscular Injection in Chinese Adult Volunteers

NCT05625477 is registered in ClinicalTrials.gov with Zhuhai Trinomab Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05625477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05625477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Dose-Finding Phase II Study to Compare the Anti-tetanus Neutralizing Antibody Titers and Safety of TNM002 Injection With Human Tetanus Immunoglobulin or Placebo Following a Single Intramuscular Injection in Chinese Adult Volunteers
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2022
Completion date
October 18, 2022
Enrollment
240 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

tetanus